You are here

evorpacept

ALX lays off 30% of staff to pay for more trials of CD47 blocker

Fierce Biotech

Wed, 03/5/25 - 12:00 pm

clinical trials

squamous cell carcinoma of the head and neck

ALX Oncology Shares Drop 15% Following Positive Phase 2

Yahoo/Guru Focus

Fri, 01/24/25 - 11:26 am

clinical trials

gastroesophageal cancer

ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

Clinical Trials Arena

Thu, 08/1/24 - 11:12 am

clinical trials

gastroesophageal cancer

ALX follows Gilead in axing CD47 blood cancer trials as data disappoint

Fierce Biotech

Fri, 08/11/23 - 10:09 am

Gilead Sciences

clinical trials

ALX and Sanofi partner to start Phase l/ll trial of RRMM combo therapy

Clinical Trials Arena

Wed, 04/26/23 - 10:26 am

clinical trials

relapsed or refractory multiple myeloma